Ionis Pharma Urges Investors to Reject the Below-the-Market Offer By Post author:Sam Post published:August 23, 2017 Post category:BioPharma August 24, 2017By Mark Terry… Source: BioSpace You Might Also Like Mirati Therapeutics To Participate In Immuno-Oncology Panel Discussion At The 2017 Conference August 30, 2017 “An Unrelenting Disaster Zone”: Merck’s Alzheimer’s Drug Fails in Phase III February 13, 2018 Chromocell Appoints Vice President Of Clinical Development May 7, 2017
Mirati Therapeutics To Participate In Immuno-Oncology Panel Discussion At The 2017 Conference August 30, 2017
